Cabaletta Bio (NASDAQ: CABA) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Cabaletta’s safety data from the second dose cohort at a dose of 100M DSG3-CAART cells in the DesCAARTes Phase 1 in mucosal pemphigus vulgaris continue to demonstrate no clinically relevant adverse events or DLTs observed during the 28-day monitoring period following infusion. We find today’s announcement especially encouraging, as the data demonstrate the potential for persistent activity and dosing approaching that of oncology but without the need for preconditioning, which we believe makes the approach highly attractive for non-oncology conditions. With dosing underway in Cohort 3, at a dose of 500M DSG3-CAART cells, everything appears on track with this novel approach to treating autoimmune disorders, with initial target engagement/efficacy data expected in the coming months.”
To request access to the full report, visit https://ibn.fm/KO3N2
About Cabaletta Bio Inc.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (“CABA(TM)”) platform, in combination with Cabaletta’s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The company’s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes(TM) phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes(TM) Phase 1 clinical trial, visit www.CabalettaBio.com/patients/descaartes-phase-1-trial. The company’s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis. For more information, visit the company’s website at www.CabalettaBio.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.